CN110157673A - A three-dimensional model of tumor cell and its construction method and application - Google Patents
A three-dimensional model of tumor cell and its construction method and application Download PDFInfo
- Publication number
- CN110157673A CN110157673A CN201910470644.XA CN201910470644A CN110157673A CN 110157673 A CN110157673 A CN 110157673A CN 201910470644 A CN201910470644 A CN 201910470644A CN 110157673 A CN110157673 A CN 110157673A
- Authority
- CN
- China
- Prior art keywords
- cells
- tumor
- mixed cell
- cell
- tumor cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004881 tumor cell Anatomy 0.000 title claims abstract description 80
- 238000010276 construction Methods 0.000 title claims abstract description 17
- 210000004027 cell Anatomy 0.000 claims abstract description 88
- 239000000243 solution Substances 0.000 claims abstract description 53
- 229920000615 alginic acid Polymers 0.000 claims abstract description 39
- 229940072056 alginate Drugs 0.000 claims abstract description 37
- 239000006285 cell suspension Substances 0.000 claims abstract description 34
- 239000004005 microsphere Substances 0.000 claims abstract description 26
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 24
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 23
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 22
- 159000000007 calcium salts Chemical class 0.000 claims abstract description 18
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 14
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 14
- 238000011156 evaluation Methods 0.000 claims abstract description 11
- 239000012266 salt solution Substances 0.000 claims abstract description 11
- 238000012216 screening Methods 0.000 claims abstract description 10
- 239000000661 sodium alginate Substances 0.000 claims description 21
- 229940005550 sodium alginate Drugs 0.000 claims description 21
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 13
- 235000010413 sodium alginate Nutrition 0.000 claims description 13
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 11
- 206010060862 Prostate cancer Diseases 0.000 claims description 8
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 8
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 239000001110 calcium chloride Substances 0.000 claims description 5
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010046798 Uterine leiomyoma Diseases 0.000 claims description 3
- 201000010260 leiomyoma Diseases 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 230000012010 growth Effects 0.000 abstract description 9
- 238000001727 in vivo Methods 0.000 abstract description 6
- 238000012827 research and development Methods 0.000 abstract description 4
- 230000005847 immunogenicity Effects 0.000 abstract description 3
- 239000011259 mixed solution Substances 0.000 abstract description 3
- 238000003501 co-culture Methods 0.000 abstract description 2
- 239000000463 material Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 6
- 238000004113 cell culture Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 239000000648 calcium alginate Substances 0.000 description 2
- 235000010410 calcium alginate Nutrition 0.000 description 2
- 229960002681 calcium alginate Drugs 0.000 description 2
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000012606 in vitro cell culture Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241001474374 Blennius Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000003592 biomimetic effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2503/00—Use of cells in diagnostics
- C12N2503/04—Screening or testing on artificial tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
本发明属于肿瘤细胞三维培养技术领域,尤其涉及一种肿瘤细胞三维模型及其构建方法和应用。本发明中,在含有肿瘤细胞和成纤维细胞的混合细胞悬浮液中加入海藻酸盐溶液,得到混合细胞‑海藻酸盐溶液,再将混合细胞‑海藻酸盐溶液滴于钙盐溶液中得到混合细胞微球,本发明采用海藻酸盐与钙盐进行交联制备微球作为细胞支架,降低了肿瘤细胞进行三维培养的成本,海藻酸盐有着良好的生物相容性和非免疫原性,能够为细胞提供良好的三维生长环境,并且,本发明将肿瘤细胞与成纤维细胞三维共培养,能够更准确地模拟肿瘤细胞在体内的生存环境,使得构建的肿瘤细胞三维模型应用于抗肿瘤药物的筛选和/或评价更为准确、可靠,能够降低抗肿瘤药物研发的成本。
The invention belongs to the technical field of three-dimensional culture of tumor cells, and in particular relates to a three-dimensional model of tumor cells and a construction method and application thereof. In the present invention, an alginate solution is added to a mixed cell suspension containing tumor cells and fibroblasts to obtain a mixed cell-alginate solution, and then the mixed cell-alginate solution is dropped into a calcium salt solution to obtain a mixed solution Cell microspheres, the invention adopts alginate and calcium salt to cross-link to prepare microspheres as cell scaffolds, which reduces the cost of three-dimensional culture of tumor cells. Alginate has good biocompatibility and non-immunogenicity, and can Provide a good three-dimensional growth environment for cells, and the present invention co-cultures tumor cells and fibroblasts three-dimensionally, which can more accurately simulate the living environment of tumor cells in vivo, so that the constructed three-dimensional tumor cell model can be used for anti-tumor drugs. Screening and/or evaluation is more accurate and reliable, which can reduce the cost of anti-tumor drug research and development.
Description
技术领域technical field
本发明属于肿瘤细胞三维培养技术领域,尤其涉及一种肿瘤细胞三维模型及其构建方法和应用。The invention belongs to the technical field of three-dimensional culture of tumor cells, and in particular relates to a three-dimensional model of tumor cells and a construction method and application thereof.
背景技术Background technique
目前,基于二维细胞培养模型的药物检测仍然是肿瘤研究的主要方法。但是,此方法无法准确地模拟肿瘤细胞复杂的生长环境,因此采用二维细胞培养模型所进行的药物评价是不准确的,构建一个能够更准确模拟人体肿瘤生长环境且经济高效的模型替代二维细胞模型,对于药物开发和评价筛选至关重要。Currently, drug detection based on two-dimensional cell culture models is still the main method for tumor research. However, this method cannot accurately simulate the complex growth environment of tumor cells, so the drug evaluation using a two-dimensional cell culture model is inaccurate, and a cost-effective model that can more accurately simulate the human tumor growth environment can be constructed to replace the two-dimensional cell culture model. Cell models are essential for drug development and evaluation screening.
要提高抗肿瘤药物评价的准确性与可靠性,就要改变传统的体外细胞培养的模型,根据目前的一些研究表明,三维体外细胞培养能够再现生理微环境并与体内的生理反应高度一致。构建肿瘤细胞三维模型需要特殊材料作为细胞支架以支持细胞生长,目前作为细胞支架的材料包括天然细胞外基质材料、合成生物材料、天然纯化分子材料等,这些材料有着良好的生物相容性和物理化学性质,能让细胞在其中保持生长活性。但是,上述作为细胞支架的材料存在成本昂贵的缺陷。To improve the accuracy and reliability of antitumor drug evaluation, it is necessary to change the traditional in vitro cell culture model. According to some current studies, three-dimensional in vitro cell culture can reproduce the physiological microenvironment and is highly consistent with the physiological response in vivo. The construction of three-dimensional tumor cell models requires special materials as cell scaffolds to support cell growth. At present, the materials used as cell scaffolds include natural extracellular matrix materials, synthetic biological materials, natural purified molecular materials, etc. These materials have good biocompatibility and physical properties. Chemical properties that allow cells to remain active in growth. However, the above-mentioned materials used as cell scaffolds have the disadvantage of being expensive.
发明内容SUMMARY OF THE INVENTION
有鉴于此,本发明提供了一种肿瘤细胞三维模型及其构建方法和应用,用于解决采用现有材料作为细胞支架成本昂贵的问题。In view of this, the present invention provides a three-dimensional tumor cell model and its construction method and application, which are used to solve the problem of high cost of using existing materials as cell scaffolds.
本发明的具体技术方案如下:The concrete technical scheme of the present invention is as follows:
一种肿瘤细胞三维模型的构建方法,包括以下步骤:A method for constructing a three-dimensional model of tumor cells, comprising the following steps:
a)将肿瘤细胞和成纤维细胞配制成混合细胞悬浮液,在所述混合细胞悬浮液中加入海藻酸盐溶液,得到混合细胞-海藻酸盐溶液;a) preparing tumor cells and fibroblasts into a mixed cell suspension, adding an alginate solution to the mixed cell suspension to obtain a mixed cell-alginate solution;
b)将所述混合细胞-海藻酸盐溶液滴于钙盐溶液中,得到混合细胞微球;b) dropping the mixed cell-alginate solution in the calcium salt solution to obtain mixed cell microspheres;
c)将所述混合细胞微球置于培养液中培养,得到肿瘤细胞三维模型。c) placing the mixed cell microspheres in a culture medium to obtain a three-dimensional model of tumor cells.
优选的,所述混合细胞悬浮液中所述肿瘤细胞和所述成纤维细胞的数量比例为(2~3):(1~2)。Preferably, the number ratio of the tumor cells and the fibroblasts in the mixed cell suspension is (2-3): (1-2).
优选的,所述肿瘤细胞在所述混合细胞悬浮液中的浓度为1*105个/ml~5*106个/ml;Preferably, the concentration of the tumor cells in the mixed cell suspension is 1*10 5 cells/ml to 5*10 6 cells/ml;
所述成纤维细胞在所述混合细胞悬浮液中的浓度为1*105个/ml~5*106个/ml。The concentration of the fibroblasts in the mixed cell suspension is 1*10 5 cells/ml to 5*10 6 cells/ml.
优选的,所述肿瘤细胞选自前列腺癌细胞、乳腺癌细胞、子宫肌瘤细胞或肝癌细胞。Preferably, the tumor cells are selected from prostate cancer cells, breast cancer cells, uterine fibroids or liver cancer cells.
优选的,所述海藻酸盐为海藻酸钠;Preferably, the alginate is sodium alginate;
所述钙盐选自氯化钙或硫酸钙。The calcium salt is selected from calcium chloride or calcium sulfate.
优选的,所述海藻酸盐溶液的质量体积比浓度为2%~4%;Preferably, the mass volume concentration of the alginate solution is 2% to 4%;
所述混合细胞悬浮液与所述海藻酸盐溶液的质量比为(1~3):(1~3)。The mass ratio of the mixed cell suspension to the alginate solution is (1-3): (1-3).
优选的,所述钙盐溶液的浓度为0.1~0.2mol/L。Preferably, the concentration of the calcium salt solution is 0.1-0.2 mol/L.
优选的,所述混合细胞微球与所述培养液的体积比为(1~3):(1~3)。Preferably, the volume ratio of the mixed cell microspheres to the culture solution is (1-3):(1-3).
本发明还提供了上述技术方案所述构建方法得到的肿瘤细胞三维模型。The present invention also provides the three-dimensional tumor cell model obtained by the construction method described in the above technical solution.
本发明还提供了上述技术方案所述肿瘤细胞三维模型在抗肿瘤药物筛选和/或评价中的应用。The present invention also provides the application of the three-dimensional tumor cell model described in the above technical solution in the screening and/or evaluation of anti-tumor drugs.
综上所述,本发明提供了一种肿瘤细胞三维模型的构建方法,包括以下步骤:a)将肿瘤细胞和成纤维细胞配制成混合细胞悬浮液,在所述混合细胞悬浮液中加入海藻酸盐溶液,得到混合细胞-海藻酸盐溶液;b)将所述混合细胞-海藻酸盐溶液滴于钙盐溶液中,得到混合细胞微球;c)将所述混合细胞微球置于培养液中培养,得到肿瘤细胞三维模型。本发明中,在含有肿瘤细胞和成纤维细胞的混合细胞悬浮液中加入海藻酸盐溶液,得到混合细胞-海藻酸盐溶液,再将混合细胞-海藻酸盐溶液滴于钙盐溶液中得到混合细胞微球,本发明采用海藻酸盐与钙盐进行交联制备微球作为细胞支架,降低了肿瘤细胞进行三维培养的成本,海藻酸盐有着良好的生物相容性和非免疫原性,能够为细胞提供良好的三维生长环境,并且,本发明将肿瘤细胞与成纤维细胞三维共培养,能够更准确地模拟肿瘤细胞在体内的生存环境,使得构建的肿瘤细胞三维模型应用于抗肿瘤药物的筛选和/或评价更为准确、可靠,能够降低抗肿瘤药物研发的成本。In summary, the present invention provides a method for constructing a three-dimensional tumor cell model, comprising the following steps: a) preparing a mixed cell suspension from tumor cells and fibroblasts, and adding alginic acid to the mixed cell suspension salt solution to obtain a mixed cell-alginate solution; b) dropping the mixed cell-alginate solution in a calcium salt solution to obtain a mixed cell microsphere; c) placing the mixed cell microsphere in a culture solution 3-D model of tumor cells was obtained. In the present invention, an alginate solution is added to the mixed cell suspension containing tumor cells and fibroblasts to obtain a mixed cell-alginate solution, and then the mixed cell-alginate solution is dropped into a calcium salt solution to obtain a mixed solution Cell microspheres, the invention adopts alginate and calcium salt to cross-link to prepare microspheres as cell scaffolds, which reduces the cost of three-dimensional culture of tumor cells. Alginate has good biocompatibility and non-immunogenicity, and can Provides a good three-dimensional growth environment for cells, and the present invention co-cultures tumor cells and fibroblasts three-dimensionally, which can more accurately simulate the living environment of tumor cells in vivo, so that the constructed three-dimensional tumor cell model can be used for anti-tumor drugs. Screening and/or evaluation is more accurate and reliable, which can reduce the cost of anti-tumor drug research and development.
附图说明Description of drawings
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。In order to illustrate the embodiments of the present invention or the technical solutions in the prior art more clearly, the following briefly introduces the accompanying drawings that are required in the description of the embodiments or the prior art.
图1为本发明实施例中提供的一种肿瘤细胞三维模型中细胞在第4天、第8天、第10天和第12天的存活率。FIG. 1 is the survival rate of cells on the 4th day, the 8th day, the 10th day and the 12th day in a three-dimensional tumor cell model provided in the embodiment of the present invention.
具体实施方式Detailed ways
本发明提供了一种肿瘤细胞三维模型及其构建方法和应用,用于解决采用现有材料作为细胞支架成本昂贵的问题。The present invention provides a three-dimensional model of tumor cells and a construction method and application thereof, which are used to solve the problem of high cost of using existing materials as cell scaffolds.
下面将对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。The technical solutions in the embodiments of the present invention will be described clearly and completely below. Obviously, the described embodiments are only a part of the embodiments of the present invention, rather than all the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those of ordinary skill in the art without creative efforts shall fall within the protection scope of the present invention.
一种肿瘤细胞三维模型的构建方法,包括以下步骤:A method for constructing a three-dimensional model of tumor cells, comprising the following steps:
a)将肿瘤细胞和成纤维细胞配制成混合细胞悬浮液,在所述混合细胞悬浮液中加入海藻酸盐溶液,得到混合细胞-海藻酸盐溶液;a) preparing tumor cells and fibroblasts into a mixed cell suspension, adding an alginate solution to the mixed cell suspension to obtain a mixed cell-alginate solution;
b)将所述混合细胞-海藻酸盐溶液滴于钙盐溶液中,得到混合细胞微球;b) dropping the mixed cell-alginate solution in the calcium salt solution to obtain mixed cell microspheres;
c)将所述混合细胞微球置于培养液中培养,得到肿瘤细胞三维模型。c) placing the mixed cell microspheres in a culture medium to obtain a three-dimensional model of tumor cells.
本发明中,在含有肿瘤细胞和成纤维细胞的混合细胞悬浮液中加入海藻酸盐溶液,得到混合细胞-海藻酸盐溶液,再将混合细胞-海藻酸盐溶液滴于钙盐溶液中得到混合细胞微球,本发明采用海藻酸盐与钙盐进行交联制备微球作为细胞支架,降低了肿瘤细胞进行三维培养的成本,海藻酸盐有着良好的生物相容性和非免疫原性,海藻酸盐与钙盐交联得到的海藻酸钙水凝胶为疏水多孔的结构,便于细胞的附着与生长,以及营养物质的输送,能够为细胞提供良好的三维生长环境。并且,采用海藻酸盐与钙盐进行交联制备微球作为细胞支架,成本低,制作过程简单、容易操作。In the present invention, an alginate solution is added to the mixed cell suspension containing tumor cells and fibroblasts to obtain a mixed cell-alginate solution, and then the mixed cell-alginate solution is dropped into a calcium salt solution to obtain a mixed solution Cell microspheres, the invention adopts alginate and calcium salt to cross-link to prepare microspheres as cell scaffolds, which reduces the cost of three-dimensional culture of tumor cells, alginate has good biocompatibility and non-immunogenicity, and seaweed The calcium alginate hydrogel obtained by the cross-linking of acid salts and calcium salts has a hydrophobic and porous structure, which is convenient for the attachment and growth of cells, as well as the transport of nutrients, and can provide a good three-dimensional growth environment for cells. In addition, using alginate and calcium salt to cross-link to prepare microspheres as cell scaffolds, the cost is low, the manufacturing process is simple, and the operation is easy.
在体内,肿瘤细胞与多种细胞共同生存,它们之间有着各种各样的相互作用,这也导致肿瘤细胞单独培养情况下的生理特性和在人体内生长有着较大的差异。本发明将肿瘤细胞与成纤维细胞三维共培养,构建的肿瘤细胞三维模型内具有复杂的细胞与细胞和细胞与基质相互作用的三维网络,能够更准确地模拟肿瘤细胞在体内的生存环境,使用该肿瘤细胞三维模型进行抗肿瘤药物的筛选和/或评价时,肿瘤细胞不仅与药物的渗透作用有关,并且成纤维细胞分泌因子的分布和功能也会影响肿瘤细胞的生长、分化和死亡,使得构建的肿瘤细胞三维模型应用于抗肿瘤药物的筛选和/或评价更为准确、可靠,能够降低抗肿瘤药物研发的成本。In vivo, tumor cells co-exist with a variety of cells, and there are various interactions between them, which also leads to great differences in the physiological characteristics of tumor cells when they are cultured alone and when they grow in the human body. In the present invention, tumor cells and fibroblasts are co-cultured in three dimensions, and the three-dimensional model of tumor cells constructed has a complex three-dimensional network of interaction between cells and cells and cells and matrices, which can more accurately simulate the living environment of tumor cells in vivo. When the three-dimensional tumor cell model is used for the screening and/or evaluation of anti-tumor drugs, tumor cells are not only related to the penetration of drugs, but also the distribution and function of fibroblast-secreted factors also affect the growth, differentiation and death of tumor cells, making The constructed three-dimensional tumor cell model is more accurate and reliable when applied to the screening and/or evaluation of anti-tumor drugs, and can reduce the cost of anti-tumor drug research and development.
本发明实施例中,混合细胞悬浮液中肿瘤细胞和成纤维细胞的数量比例为(2~3):(1~2),优选为2:1。In the embodiment of the present invention, the number ratio of tumor cells and fibroblasts in the mixed cell suspension is (2-3):(1-2), preferably 2:1.
本发明实施例中,肿瘤细胞在混合细胞悬浮液中的浓度为1*105个/ml~5*106个/ml,优选为1*106个/ml;In the embodiment of the present invention, the concentration of tumor cells in the mixed cell suspension is 1*10 5 cells/ml to 5*10 6 cells/ml, preferably 1*10 6 cells/ml;
成纤维细胞在混合细胞悬浮液中的浓度为1*105个/ml~5*106个/ml,优选为5*105个/ml。The concentration of fibroblasts in the mixed cell suspension is 1*10 5 cells/ml to 5*10 6 cells/ml, preferably 5*10 5 cells/ml.
本发明实施例中,肿瘤细胞选自前列腺癌细胞、乳腺癌细胞、子宫肌瘤细胞或肝癌细胞。In the embodiment of the present invention, the tumor cells are selected from prostate cancer cells, breast cancer cells, uterine fibroids or liver cancer cells.
本发明实施例中,需要根据肿瘤在体内的生长环境、肿瘤的组成结构来选取与肿瘤细胞共培养的细胞,需要该细胞的生长、分裂周期与癌细胞相近,培养条件相似(可用同种培养基培养)。肿瘤细胞优选为前列腺癌细胞,前列腺癌细胞的生长、分裂周期与成纤维细胞的相差很小,细胞培养的条件相近,可用同种培养基培养。并且,前列腺癌细胞的生长速度快、对生长环境的要求不高,易于培养,适合短时间培养大量的细胞进行实验。In the embodiment of the present invention, it is necessary to select cells co-cultured with tumor cells according to the growth environment of the tumor in vivo and the composition of the tumor. base culture). The tumor cells are preferably prostate cancer cells. The growth and division cycles of prostate cancer cells are very different from those of fibroblasts. The cell culture conditions are similar and can be cultured in the same medium. In addition, prostate cancer cells grow rapidly, do not have high requirements on the growth environment, are easy to culture, and are suitable for culturing a large number of cells in a short period of time for experiments.
前列腺癌细胞选自PC3、LNCaP、DU145、VCaP或VLcop;成纤维细胞选自3T3、BMF、HPF、HFF或BJ。Prostate cancer cells are selected from PC3, LNCaP, DU145, VCaP or VLcop; fibroblasts are selected from 3T3, BMF, HPF, HFF or BJ.
本发明实施例中,海藻酸盐为海藻酸钠,海藻酸钠是一种提取于藻类植物的天然多糖,成本低、易于制作;In the embodiment of the present invention, the alginate is sodium alginate, and sodium alginate is a natural polysaccharide extracted from algae, which is low in cost and easy to manufacture;
钙盐选自氯化钙或硫酸钙。The calcium salt is selected from calcium chloride or calcium sulfate.
本发明实施例中,海藻酸盐溶液的质量浓度为2%~4%,优选为3.5%,实验结果表明细胞在海藻酸钠质量体积比浓度为3.5%的小球中,存活率更高、更稳定。In the embodiment of the present invention, the mass concentration of the alginate solution is 2% to 4%, preferably 3.5%. The experimental results show that the cells have a higher survival rate in the pellets with a concentration of 3.5% by mass of sodium alginate. more stable.
混合细胞悬浮液与海藻酸盐溶液的质量比为(1~3):(1~3),优选为1:1。The mass ratio of the mixed cell suspension to the alginate solution is (1-3):(1-3), preferably 1:1.
海藻酸盐的分子量优选为216.12303。The molecular weight of the alginate is preferably 216.12303.
本发明实施例中,钙盐溶液的浓度为0.1~0.2mol/L,优选为0.1mol/L。In the embodiment of the present invention, the concentration of the calcium salt solution is 0.1-0.2 mol/L, preferably 0.1 mol/L.
本发明实施例中,混合细胞微球与培养液的体积比为(1~3):(1~3),优选为1:3。In the embodiment of the present invention, the volume ratio of the mixed cell microspheres to the culture solution is (1-3):(1-3), preferably 1:3.
本发明实施例中,步骤a)之前,还包括:将肿瘤细胞和成纤维细胞分别进行平面培养。In the embodiment of the present invention, before step a), the method further includes: culturing tumor cells and fibroblasts on a plane respectively.
步骤a)肿瘤细胞为第3代至第6代的肿瘤细胞,成纤维细胞为第3代至第6代的成纤维细胞。Step a) The tumor cells are tumor cells of the third to sixth passages, and the fibroblasts are the fibroblasts of the third to sixth passages.
本发明还提供了上述技术方案构建方法得到的肿瘤细胞三维模型。The present invention also provides a three-dimensional tumor cell model obtained by the construction method of the above technical solution.
本发明还提供了上述技术方案肿瘤细胞三维模型在抗肿瘤药物筛选和/或评价中的应用。The present invention also provides the application of the three-dimensional tumor cell model of the above technical solution in the screening and/or evaluation of anti-tumor drugs.
本发明肿瘤细胞三维模型使用操作简单、实验环境要求较低,减小了实验失误的可能性,并且应用于抗肿瘤药物的筛选和/或评价中准确、可靠,能够降低抗肿瘤药物研发的成本。The tumor cell three-dimensional model of the present invention is simple to use and has low requirements on the experimental environment, reduces the possibility of experimental errors, is accurate and reliable when applied to the screening and/or evaluation of anti-tumor drugs, and can reduce the cost of research and development of anti-tumor drugs .
本发明肿瘤细胞三维模型可应用于新型抗癌药物的筛选与检测,由于细胞培养在海藻酸钙微球中,方便随时取出检测,以研究不同作用时间药物对肿瘤细胞的作用效果。本发明肿瘤细胞三维模型还可以搭配Transwell、微流控等其它装置,再构建出新的更具仿生效果的肿瘤细胞模型。The tumor cell three-dimensional model of the invention can be applied to the screening and detection of new anticancer drugs. Since the cells are cultured in calcium alginate microspheres, it is convenient to take out and test at any time, so as to study the effect of drugs on tumor cells at different action times. The three-dimensional tumor cell model of the present invention can also be matched with other devices such as Transwell and microfluidics to construct a new tumor cell model with more biomimetic effects.
为了进一步理解本发明,下面结合具体实施例对本发明进行详细阐述。In order to further understand the present invention, the present invention will be described in detail below with reference to specific embodiments.
实施例1Example 1
本实施例进行肿瘤细胞三维模型的制备,包括以下步骤:In this example, the preparation of a three-dimensional tumor cell model includes the following steps:
1)海藻酸钠溶液和氯化钙溶液的配制1) Preparation of sodium alginate solution and calcium chloride solution
称量海藻酸钠粉末加入到试剂瓶中并加入去离子水,然后放入磁力搅拌子,放在磁力搅拌器上进行12h~24h搅拌,配制得到质量浓度分别为3%、3.5%和4%的海藻酸钠溶液。Weigh the sodium alginate powder into the reagent bottle and add deionized water, then put it into a magnetic stirrer, and put it on the magnetic stirrer for 12h to 24h stirring, and the mass concentrations are 3%, 3.5% and 4% respectively. of sodium alginate solution.
称量氯化钙粉末加入到试剂瓶中并加入去离子水,配制得到0.1mol/L的氯化钙溶液。Calcium chloride powder was weighed into a reagent bottle and deionized water was added to prepare a 0.1 mol/L calcium chloride solution.
将海藻酸钠溶液和氯化钙溶液一起放入高温高压灭菌机里进行125℃灭菌15分钟,海藻酸钠溶液和氯化钙溶液配制完成。Put the sodium alginate solution and the calcium chloride solution together into a high temperature and high pressure sterilizer for sterilization at 125°C for 15 minutes, and the sodium alginate solution and the calcium chloride solution are prepared.
2)前列腺癌细胞(PC3)和成纤维细胞(3T3)的平面培养2) Flat culture of prostate cancer cells (PC3) and fibroblasts (3T3)
取出装有PC3细胞的冷冻管,水浴融化,离心,用含1%双抗、10%胎牛血清的低糖DMEM培养液培养PC3细胞,每2天换一次液。待细胞铺满培养瓶底75%-80%时,用胰蛋白酶进行消化,在显微镜中观察PC3细胞至PC3细胞外形呈椭圆状,即将脱壁分离时,终止消化。取PC3细胞悬液离心,弃上清液,加入适量新鲜的培养液重悬,配成细胞浓度为(1*106个/ml)的PC3细胞悬浮液。The cryovial containing PC3 cells was taken out, thawed in a water bath, centrifuged, and the PC3 cells were cultured with low-glucose DMEM medium containing 1% double antibody and 10% fetal bovine serum, and the medium was changed every 2 days. When the cells are 75%-80% confluent at the bottom of the culture flask, digest with trypsin, observe the PC3 cells under the microscope until the shape of the PC3 cells is oval. Centrifuge the PC3 cell suspension, discard the supernatant, add an appropriate amount of fresh culture medium to resuspend, and prepare a PC3 cell suspension with a cell concentration of (1*10 6 cells/ml).
取出装有3T3细胞的冷冻管,水浴融化,离心,用含1%双抗、10%胎牛血清的低糖DMEM培养液培养3T3细胞,每2天换一次液。待细胞铺满瓶底75%-80%时,用胰蛋白酶进行消化,在显微镜中观察3T3细胞至3T3细胞外形呈椭圆状,即将脱壁分离时,终止消化。取3T3细胞悬液离心,弃上清液,加入适量新鲜的培养液重悬,得到3T3细胞悬浮液,3T3细胞悬浮液的细胞浓度与PC3细胞悬浮液的细胞浓度一致。The cryovial containing 3T3 cells was taken out, thawed in a water bath, centrifuged, and 3T3 cells were cultured in low-glucose DMEM medium containing 1% double antibody and 10% fetal bovine serum, and the medium was changed every 2 days. When the cells cover 75%-80% of the bottom of the flask, digest with trypsin, observe the 3T3 cells under a microscope until the 3T3 cells are oval in shape, and stop the digestion when they are about to detach from the wall. The 3T3 cell suspension was centrifuged, the supernatant was discarded, and an appropriate amount of fresh culture medium was added to resuspend to obtain a 3T3 cell suspension. The cell concentration of the 3T3 cell suspension was consistent with that of the PC3 cell suspension.
3)制备混合细胞微球3) Preparation of mixed cell microspheres
将PC3细胞悬浮液和3T3细胞悬浮液以1:1比例加入至离心管中,配置成总细胞浓度为1×106/mL的混合细胞悬浮液,然后取三支离心管,往其中分别加入质量浓度分别为3%、3.5%和4%的海藻酸钠溶液,再以海藻酸钠溶液:混合细胞悬浮液比例1:1加入混合细胞悬浮液,然后用移液枪将溶液吹打均匀,得到混合细胞-海藻酸钠溶液1、混合细胞-海藻酸钠溶液2和混合细胞-海藻酸钠溶液3。Add PC3 cell suspension and 3T3 cell suspension to a centrifuge tube at a ratio of 1:1 to prepare a mixed cell suspension with a total cell concentration of 1×10 6 /mL, then take three centrifuge tubes and add them to them respectively. The sodium alginate solution with the mass concentration of 3%, 3.5% and 4%, respectively, was added to the mixed cell suspension in the ratio of sodium alginate solution: mixed cell suspension to 1:1, and then the solution was pipetted evenly with a pipette gun to obtain Mixed cells-sodium alginate solution 1, mixed cells-sodium alginate solution 2, and mixed cells-sodium alginate solution 3.
取培养皿,加入0.1mol/L的等量氯化钙溶液,使用注射器分别吸取混合细胞-海藻酸钠溶液1、混合细胞-海藻酸钠溶液2和混合细胞-海藻酸钠溶液3,将注射器针头悬空于培养皿中氯化钙液面以上,缓慢地以1滴/秒的速度滴出溶液,使混合细胞-海藻酸钠溶液1、混合细胞-海藻酸钠溶液2和混合细胞-海藻酸钠溶液3与氯化钙溶液分别交联形成混合细胞微球1、混合细胞微球2和混合细胞微球3,再将混合细胞微球1、混合细胞微球2和混合细胞微球3培养于新鲜的含1%双抗、10%胎牛血清的低糖DMEM培养液中,得到肿瘤细胞三维模型1、肿瘤细胞三维模型2和肿瘤细胞三维模型3。其中,肿瘤细胞三维模型1、肿瘤细胞三维模型2和肿瘤细胞三维模型3均设5组平行试验。Take the petri dish, add 0.1mol/L calcium chloride solution in the same amount, use a syringe to draw mixed cell-sodium alginate solution 1, mixed cell-sodium alginate solution 2, and mixed cell-sodium alginate solution 3, respectively. The needle is suspended above the calcium chloride liquid level in the petri dish, and the solution is slowly dripped at a rate of 1 drop/second, so that the mixed cell-sodium alginate solution 1, the mixed cell-sodium alginate solution 2 and the mixed cell-alginic acid The sodium solution 3 and the calcium chloride solution are respectively cross-linked to form mixed cell microspheres 1, mixed cell microspheres 2 and mixed cell microspheres 3, and then the mixed cell microspheres 1, mixed cell microspheres 2 and mixed cell microspheres 3 are cultured In fresh low-glucose DMEM medium containing 1% double antibody and 10% fetal bovine serum, three-dimensional tumor cell model 1, three-dimensional tumor cell model 2 and three-dimensional tumor cell model 3 were obtained. Among them, 5 groups of parallel experiments were set up for tumor cell 3D model 1, tumor cell 3D model 2 and tumor cell 3D model 3.
将肿瘤细胞三维模型1、肿瘤细胞三维模型2和肿瘤细胞三维模型3分别在第0天、第4天、第8天、第10天和第12天进行细胞收集并测定细胞的存活率,以第0天细胞存活率为100%计。请参阅图1,为本发明实施例中提供的一种肿瘤细胞三维模型中细胞在第4天、第8天、第10天和第12天的存活率,结果表明,采用质量浓度为3.5%的海藻酸钠构建的肿瘤细胞三维模型的细胞存活率最高。The tumor cell three-dimensional model 1, tumor cell three-dimensional model 2 and tumor cell three-dimensional model 3 were collected on the 0th day, the 4th day, the 8th day, the 10th day and the 12th day, respectively, and the cell viability was determined to determine the cell viability. Day 0 cell viability was counted as 100%. Please refer to FIG. 1, which is the survival rate of cells in a three-dimensional tumor cell model provided in the embodiment of the present invention on the 4th day, the 8th day, the 10th day and the 12th day. The results show that the mass concentration is 3.5%. The 3D model of tumor cells constructed with sodium alginate had the highest cell survival rate.
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。The above are only the preferred embodiments of the present invention. It should be pointed out that for those skilled in the art, without departing from the principles of the present invention, several improvements and modifications can be made. It should be regarded as the protection scope of the present invention.
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910470644.XA CN110157673A (en) | 2019-05-31 | 2019-05-31 | A three-dimensional model of tumor cell and its construction method and application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910470644.XA CN110157673A (en) | 2019-05-31 | 2019-05-31 | A three-dimensional model of tumor cell and its construction method and application |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110157673A true CN110157673A (en) | 2019-08-23 |
Family
ID=67630858
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910470644.XA Pending CN110157673A (en) | 2019-05-31 | 2019-05-31 | A three-dimensional model of tumor cell and its construction method and application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110157673A (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111893096A (en) * | 2020-09-04 | 2020-11-06 | 刘特 | Method for preparing genitourinary system tumor cell iron death model based on ferric ammonium citrate and application of prepared antitumor drug |
CN112430574A (en) * | 2020-11-27 | 2021-03-02 | 哈尔滨工业大学 | Construction method of magnetic control in-vitro tumor array |
CN112501120A (en) * | 2020-11-20 | 2021-03-16 | 沈阳化工大学 | Tumor cell three-dimensional model and activity detection method thereof |
CN112852738A (en) * | 2019-11-27 | 2021-05-28 | 四川省肿瘤医院 | Prostate cancer cell membrane and preparation method thereof |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010055804A1 (en) * | 2000-01-13 | 2001-12-27 | Shekhar Malathy P.V. | Three-dimensional in vitro model of human preneoplastic breast disease |
CN101157908A (en) * | 2007-01-04 | 2008-04-09 | 南京大学医学院附属鼓楼医院 | An in vitro co-culture model of tumor angiogenesis |
CN103160468A (en) * | 2011-12-19 | 2013-06-19 | 中国科学院大连化学物理研究所 | Human tumor invasion and metastasis histioid in vitro three-dimensional model and construction and evaluation thereof |
CN106148270A (en) * | 2015-04-13 | 2016-11-23 | 中国科学院大连化学物理研究所 | A kind of construction method of the three-dimensional for biological artificial liver support system micro-hepatic tissue unit |
CN108060132A (en) * | 2016-11-09 | 2018-05-22 | 复旦大学 | A kind of 3D co-culture models based on tumour cell Yu tumour associated fibroblast cell |
CN109735496A (en) * | 2019-02-22 | 2019-05-10 | 深圳市罗湖区人民医院 | A kind of tumour cell chemotherapeutics three-dimensional resistant models and its method for building up |
-
2019
- 2019-05-31 CN CN201910470644.XA patent/CN110157673A/en active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010055804A1 (en) * | 2000-01-13 | 2001-12-27 | Shekhar Malathy P.V. | Three-dimensional in vitro model of human preneoplastic breast disease |
CN101157908A (en) * | 2007-01-04 | 2008-04-09 | 南京大学医学院附属鼓楼医院 | An in vitro co-culture model of tumor angiogenesis |
CN103160468A (en) * | 2011-12-19 | 2013-06-19 | 中国科学院大连化学物理研究所 | Human tumor invasion and metastasis histioid in vitro three-dimensional model and construction and evaluation thereof |
CN106148270A (en) * | 2015-04-13 | 2016-11-23 | 中国科学院大连化学物理研究所 | A kind of construction method of the three-dimensional for biological artificial liver support system micro-hepatic tissue unit |
CN108060132A (en) * | 2016-11-09 | 2018-05-22 | 复旦大学 | A kind of 3D co-culture models based on tumour cell Yu tumour associated fibroblast cell |
CN109735496A (en) * | 2019-02-22 | 2019-05-10 | 深圳市罗湖区人民医院 | A kind of tumour cell chemotherapeutics three-dimensional resistant models and its method for building up |
Non-Patent Citations (3)
Title |
---|
AMANN 等: ""Development of a 3D angiogenesis model to study tumour –endothelial cell interactions and the effects of anti-angiogenic drugs"", 《NATURE》 * |
XIN XIN 等: ""3D cell coculture tumor model: A promising approach for future cancer drug discovery"", 《PROCESS BIOCHEMISTRY》 * |
YAQI WANG 等: ""In vitro 3D cocultured tumor-vascular barrier model based on alginate hydrogel and Transwell system for anti-cancer drug evaluation"", 《TISSUE AND CELL》 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112852738A (en) * | 2019-11-27 | 2021-05-28 | 四川省肿瘤医院 | Prostate cancer cell membrane and preparation method thereof |
CN112852738B (en) * | 2019-11-27 | 2023-02-28 | 四川省肿瘤医院 | Preparation method of prostate cancer cell membrane |
CN111893096A (en) * | 2020-09-04 | 2020-11-06 | 刘特 | Method for preparing genitourinary system tumor cell iron death model based on ferric ammonium citrate and application of prepared antitumor drug |
CN112501120A (en) * | 2020-11-20 | 2021-03-16 | 沈阳化工大学 | Tumor cell three-dimensional model and activity detection method thereof |
CN112430574A (en) * | 2020-11-27 | 2021-03-02 | 哈尔滨工业大学 | Construction method of magnetic control in-vitro tumor array |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110157673A (en) | A three-dimensional model of tumor cell and its construction method and application | |
CN110129262A (en) | A three-dimensional model of tumor cell co-culture and its construction method and application | |
JP6879517B2 (en) | Medium composition and method for culturing cells or tissues using the composition | |
CN106434562B (en) | Brain tumor in-vitro model for three-dimensional biological printing and construction method thereof | |
Liu et al. | Three-dimensional hepatic lobule-like tissue constructs using cell-microcapsule technology | |
CN111826338B (en) | Method for rapidly culturing liver bud organoid | |
CN110475860A (en) | Use the dimensional culture of the primary cancer cell of tumor tissues | |
CN113755426A (en) | Organoid culture system and organoid culture method | |
Liu et al. | Magnetically controllable 3D microtissues based on magnetic microcryogels | |
CN102399693A (en) | Simulated three-dimensional cell culture device and culture method | |
CN103351484A (en) | Micropatterned hydrogel coating, its preparation method and use | |
CN116445285B (en) | Organ-like co-culture chip, construction method and co-culture method | |
WO2014200997A2 (en) | Method for preparing three-dimensional, organotypic cell cultures and uses thereof | |
TWI666448B (en) | Method for predicting effect of drug | |
CN108118025A (en) | A kind of foundation and its application of the three-dimensional liver model based on qualitative filter paper | |
Penfornis et al. | Three dimensional tumor models for cancer studies | |
CN112961821B (en) | Method for three-dimensional culture of vascular endothelial cells | |
WO2016039391A1 (en) | Method for cell recovery | |
CN108066314A (en) | A kind of pectin is the biological microsphere preparation method and application of wall material | |
CN112813029B (en) | 3D culture method of medulloblastoma cells and application of method in drug screening | |
CN110564690A (en) | Method for constructing in-vitro GBM (GBM) invasion model based on biological three-dimensional printing | |
CN211921592U (en) | A three-dimensional lung cancer cell culture device | |
RU2814138C1 (en) | Method of co-cultivating of three-dimensional cell cultures of human lower respiratory tract to obtain cellular model for in vitro studies | |
Parias Carreño | Formation of three-dimensional cell culture of colorectal carcinoma cells for possible applications in alternative cancer treatment in vitro | |
CN118895248B (en) | Method for establishing colon cancer tumor resting cell three-dimensional model based on matrix hardness |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190823 |
|
RJ01 | Rejection of invention patent application after publication |